secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2026-09-08T21:26:46+00:00
Accession:  0001193125-26-385380
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen-BioLife merger clears HSR waiting period; stockholder vote set for Oct 5
--------------------------------------------------------------------------------

- HSR waiting period for Repligen's acquisition of BioLife expired Sept 3, 2026 at 11:59 PM ET.
- Deal terms: BioLife shareholders receive $11.25 cash plus 0.1442 Repligen shares per share.
- Special BioLife stockholder meeting scheduled Oct 5, 2026 at 9:00 AM ET to vote on merger.
- Closing still subject to BioLife stockholder adoption and other customary conditions.
- Merger agreement originally signed July 21, 2026; Repligen to acquire all BioLife stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312526385380/0001193125-26-385380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312526385380/d131600d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-385380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer